The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study.

kcl.ac.uk.2Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King’s College London, London, UK; National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London, UK; South London and Maudsley NHS Mental Health Foundation Trust, London, UK.3Addiction and Read more…

Partage le savoir

17 D2 Receptor Partial Agonists in Dual Disorders: Use of Aripiprazole in Psychotic Disorder and Comorbid Substance Use Disorder.

75mg; SD:61.23), 1 with clotiapine 20mg daily and 1 olanzapine 15mg daily. There were 6 (54.5%) polysubstance users and the substances used were cannabis (63.7%), alcohol (36.4%), stimulants (27.3%), opioids (9.1%), hallucinogens (9.1%) and sedative-hypnotics (9.1%).The mean of inpatient admissions before and after aripiprazole initiation was 1.00 (SD:1.00) and 0.18 Read more…

Partage le savoir

The Endocannabinoid System and Cannabidiol’s Promise for the Treatment of Substance Use Disorder.

Simple NCBI Directory Getting Started NCBI Education NCBI Help Manual NCBI Handbook Training & Tutorials Submit Data Resources Chemicals & BioassaysData & SoftwareDNA & RNADomains & StructuresGenes & ExpressionGenetics & MedicineGenomes & MapsHomologyLiteratureProteinsSequence AnalysisTaxonomyVariation Popular PubMed Bookshelf PubMed Central BLAST Nucleotide Genome SNP Gene Protein PubChem Featured Genetic Testing Registry Read more…

Partage le savoir

Cannabis legislation and substance use disorder treatment.

Simple NCBI Directory Getting Started NCBI Education NCBI Help Manual NCBI Handbook Training & Tutorials Submit Data Resources Chemicals & BioassaysData & SoftwareDNA & RNADomains & StructuresGenes & ExpressionGenetics & MedicineGenomes & MapsHomologyLiteratureProteinsSequence AnalysisTaxonomyVariation Popular PubMed Bookshelf PubMed Central BLAST Nucleotide Genome SNP Gene Protein PubChem Featured Genetic Testing Registry Read more…

Partage le savoir

Risks Associated with Mid level Cannabis Use Among People Treated for Alcohol Use Disorder.

lifetime DSM-IV alcohol dependence criteria and prior AUD treatment. Primary exposure was past 12-month frequency of cannabis use (weekly or more, or « heavy; » more than monthly/less than weekly or « midlevel; » less than monthly or « light; » none). Primary outcomes were past 12-month total volume, average frequency of 5 View the Original Read more…

Partage le savoir
error: Content is protected !!